Click Therapeutics Inc featured prominently this week as it sharpened its strategic focus on over-the-counter digital therapeutics while reinforcing its clinical credentials in migraine care. The company continued to position its Over-the-Counter Digital Therapeutics, or ODTx, as an “action layer” that converts passive health data into guided, evidence-based interventions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Founder and CEO David Benshoof Klein participated in the US Pharma and Biotech Summit, on a panel examining wearables, apps, and the surge of health data. His participation alongside representatives from Harvard Medical School and Ōura, under the FT Live and Endpoints News banner, highlighted Click’s growing presence in the digital health ecosystem.
Company messaging linked ODTx to the broader trend of consumer health technology, emphasizing the need to move beyond simple tracking of past behavior. Click argues that existing wellness tools often fail to guide users toward better outcomes, and it seeks to fill that gap with clinically rigorous, scalable, consumer-facing digital therapeutics.
On the clinical front, Click spotlighted a peer-reviewed npj Digital Medicine publication covering two Phase III trials of CT-132, its FDA-authorized prescription digital therapeutic for episodic migraine prevention. An integrated post-hoc analysis of the ReMMi-D and ReMMiD-C studies, involving 678 patients, showed statistically significant reductions in monthly migraine days and improvements in disability and quality-of-life metrics.
The study reported a p-value of 0.003 and no device-related adverse events, reinforcing CT-132’s safety and efficacy profile. Benefits were observed when the software was used alongside a wide range of standard migraine treatments, including CGRP inhibitors, supporting its positioning as an adjunctive option rather than a replacement.
Click also advanced its Prescription Drug Use-Related Software, or PDURS, framework, aimed at helping pharmaceutical partners create Software-Enhanced Drugs. By embedding software into FDA-authorized labels and commercialization strategies, the company seeks to extend drug lifecycles and improve outcomes in an environment of patent expirations and payer scrutiny.
Taken together, the week’s developments strengthened Click Therapeutics’ narrative as a bridge between consumer wellness apps and medical-grade software. The combination of robust late-stage migraine data, an expanding ODTx vision, and the PDURS platform underscores its ambition to be an enabling partner at the intersection of pharmaceuticals and digital health, with potential implications for future collaborations and commercial growth.